Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

Abstract Aims The GLP1 agonist lixisenatide is glucagonostatic and reduces post‐prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D). Methods In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment w...

Full description

Bibliographic Details
Main Authors: Chitrabhanu Ballav, Archana Dhere, Irene Kennedy, Olorunsola F. Agbaje, Sarah White, Rachel Franklin, Bolette Hartmann, Jens J. Holst, Rury R. Holman, Katharine R. Owen
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
GLP1 analogue
lixisenatide
type 1 diabetes
Online Access:https://doi.org/10.1002/edm2.130

Internet

https://doi.org/10.1002/edm2.130

Similar Items